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Abstract
Nucleotide metabolism was studied in erythrocytes of a mentally retarded child and family members. Partial hypoxanthine-guanine
phosphoribosyltransferase (HPRT) deficiency was found in the propositus and an asymptomatic maternal uncle. Studies in crude lysates
demonstrated decreased apparent Vmax and slightly decreased apparent Km for hypoxanthine in both HPRT-deficient subjects. Genomic DNA
analysis revealed a single nucleotide change with leucine-147 to phenylalanine substitution in both subjects; mother and grandmother were
heterozygous carriers of the same defect. This new variant has been termed HPRTPotenza. Increased erythrocyte concentration of NAD and
rate of synthesis by intact erythrocytes were found in the patient; increased activities of nicotinic acid phosphoribosyltransferase (NAPRT)
and NAD synthetase (NADs) were demonstrated in erythrocyte lysates, with normal apparent Km for their substrates and increased Vmax.
These alterations were not found in any member of the family, including the HPRT-deficient uncle. These findings show multiple
derangement of nucleotide metabolism associated with partial HPRT deficiency. The enzyme alteration was presumably not the cause of
neurological impairment since no neurological symptoms were found in the HPRT-deficient uncle, whereas they were present in the
propositus’ elder brother who had normal HPRT activity. D 2002 Elsevier Science B.V. All rights reserved.




(HPRT) (EC 2.4.2.8) catalyses salvage of the purine bases
hypoxanthine and guanine to their respective monophos-
phate nucleosides (IMP and GMP) by a 5V-phosphoribosyl-
1-pyrophosphate (PPRibP)-dependent reaction. It is a cyto-
plasmic enzyme ubiquitous in humans, displaying different
specific activities during development and in different
tissues (highest activities in testis and brain tissue) [1–3].
The genetically determined deficiency of HPRT is associ-
ated with a number of clinical phenotypes mainly depending
on the degree of deficiency. Marked uric acid overproduc-
tion resulting in hyperuricemia, nephrolithiasis and gout
presenting at an early age is a common feature. Neurological
abnormalities may be absent (previously called Kelley–
Seegmiller syndrome, KSS) [4], or mild in cases with
intermediate severity (some degree of mental retardation,
spasticity, dystonia), while the most severely affected cases
display a disabling neurological syndrome, characterized by
choreoathetosis, spasticity and compulsive self-injurious
behavior [5,6]. The latter most severe form is usually
associated with virtually complete deficiency and is known
as Lesch–Nyhan syndrome (LNS) [7]. The connection
between the neurological syndrome described in LNS
patients and HPRT deficiency is still unclear.
Human HPRT is encoded by a single structural gene at
Xq26–27 [8], consisting of nine exons and eight introns.
The entire HPRT gene has been sequenced [5], and several
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different alterations in the coding region have been de-
scribed as responsible for HPRT deficiency [5,9]. The
amino acid sequence of HPRT has been determined [10],
the physical and kinetic properties have been studied, and
different alterations of the enzyme in patients with various
degrees of deficiency have been reported [1,11–17]. Addi-
tional biochemical tissue-specific alterations have been
reported in patients with different degrees of HPRT defi-
ciency. They have mostly been detected in erythrocytes, and
include increased PPRibP concentrations (also found in
lymphoblasts and mainly fibroblasts) [18], increased UDP-
sugars (UDPs) and appreciable levels of 5-amino-4-imida-
zole-carboxamide riboside 5V-triphosphate (ZTP) [19],
increased activities of adenine phosphoribosyltransferase
(APRT) and IMP dehydrogenase [20], grossly increased
NAD concentrations [21] and GTP depletion. Involvement
of NAD and its precursors in different neurological syn-
dromes has been reported also in connection with the neu-
rotransmitter serotonine [22,23] and has stimulated research
in this rather neglected field. The increased NAD concen-
trations in erythrocytes of patients with HPRT deficiency
have not yet been explained. Altered intracellular stability
of the coenzyme can be ruled out [24], and underutilization
has not been found. We reported altered NAD synthesis in
intact erythrocytes of a patient with partial HPRT deficiency
and of an LNS patient [25] and in fibroblasts of an LNS
patient [26].
Here we present data on purines, pyridines and pyrimi-
dines in the erythrocytes of a mentally retarded child and
several family members. Partial deficiency of HPRT was
found in the propositus and an asymptomatic maternal uncle.
At molecular level, a mutation was found in exon 6. We also
detected biochemical alterations of purines and pyridines and
a significant increase in the activities of two enzymes,
nicotinic acid phosphoribosyltransferase (NAPRT) (EC
2.4.2.11) and NAD synthetase (NADs) (EC 6.3.5.1) catalys-
ing NAD synthesis from nicotinic acid (NA), previously
reported in LNS patients [27] (Fig. 1). These findings sup-
port the hypothesis that the biochemical basis for increased
NAD concentrations in erythrocytes of all HPRT-deficient
patients examined so far is increased synthesis. The clinical
manifestations are peculiar since neither the propositus nor
the uncle with the same HPRT alteration had classical KSS.
At our knowledge the propositus’ uncle is the second case
with apparently no symptoms related to enzyme deficiency
[28].
2. Materials and methods
2.1. Patients and relatives
The propositus, L.C., male, Italian, was the second child
of apparently healthy parents. At age 9 months he developed
epileptic seizures and hypotonia. At age 11 months, he
showed severe neurodevelopmental retardation, was unable
to walk and spoke only a few words. His purine metabolism
was first investigated during a screening of 150 children
with neurological impairment and partial HPRT deficiency
was found. Analyses were repeated on blood samples drawn
at the age of 14, 21, 36 months and 5 years. At 5 years he
could hardly sit, with frequent falls on his right hand side,
and could only stand and walk few steps with support.
Speech was virtually absent, and frequent stereotypes (roll-
ing) and attempts to bite himself appeared. Seizures were
frequent, with short attacks of impaired consciousness. The
following family members of L.C. were examined: the elder
brother (G.C.), age 8 years when first investigated, who had
severe neurodevelopmental retardation, drug-resistant seiz-
ures and autistic features but could sit and walk properly;
father, mother, grandmother and mother’s sisters (A, C and
R) and brother (G.M.). The latter, maternal uncle of L.C.,
age 34 years, had no clinical symptoms, not even related to
any kidney impairment, but turned out to have partial HPRT
deficiency.
Control children without metabolic dysfunction, 1–14
years of age were also examined (14 females and 12 males).
Control adults were 32 healthy volunteers 18–64 years of
age (17 females and 15 males). All subjects, including the
propositus’ parents and relatives, gave their informed con-
sent to the study. Blood samples were obtained as part of the
treatment programme or provided by voluntary donors and
thus ethical committee approval was not required.
2.2. Materials
Reagents of analytical grade were purchased from Sigma
(St. Louis, MO, USA). Chemicals for HPLC separation
were of the highest available quality.
2.3. Biochemical analysis
Non-radiochemical HPLC-linked methods previously
described [27,29–32] were used to measure purine and
pyridine nucleotide content in erythrocyte extracts, nucleo-
sides and bases in plasma extracts and urine, as well as
enzyme activities in erythrocyte lysates. The activities of the
Fig. 1. Synthesis of NAD in human erythrocytes. NA: nicotinic acid; NAm:
nicotinamide; NAMN: NA mononucleotide; NMN: NAm mononucleotide;
NAAD: NA adenine dinucleotide; NAD: NAm adenine dinucleotide;
PPRibP: 5-phosphoribosyl-1-pyrophosphate; gln: glutamine. (1) NA
phosphoribosyltransferase (EC 2.4.2.11); (2) NAm phosphoribosyltransfer-
ase (EC 2.4.2.12); (3) NAMN adenylyltransferase (EC 2.7.7.18) and NMN
adenylyltransferase (EC 2.7.7.1); (4) NAD synthetase (EC 6.3.5.1).
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following enzymes were detected by previously described
methods: HPRT, APRT [27], PPRibP synthetase (PRPS)
[30], adenosine deaminase (ADA), purine nucleoside phos-
phorylase (PNP) [21], NAPRT [29], nicotinic acid mono-
nucleotide (NAMN) and nicotinamide mononucleotide
(NMN) adenylyltransferase (NAMN/NMN-AT), NADs
[31], orotate phosphoribosyltransferase (OPRT) and OMP
decarboxylase (ODC) [32]. Urine samples were prepared
according to Simmonds et al. [33]; 24-h urine specimens
collected after 3 days of low-purine diet, preserved with
toluene, were warmed at 56 jC for 30 min with frequent
shaking to dissolve precipitated compounds, and diluted
1:31 with HPLC eluant A for HPLC processing (see below).
Conversion of 14C-labelled precursors hypoxanthine
(Hyp), adenine (Ade), NA and nicotinamide (NAm) into
nucleotides was investigated after incubation of intact cells
in isotonic PPRibP-producing medium, as previously
described [27]. Incubation time with Hyp and Ade was 1
h, and that with NA and NAm was 6 h.
Two HPLC apparatus were used, consisting of a Beck-
man System Gold Module 126, with a mod. 167 dual
channel scanning detector module (System 1), or a Beck-
man 420 controller, equipped with a mod. 163 variable
wavelength detector (System 2) in-line with a mod. 171
radioisotope detector with a packed solid scintillation cell of
125 or 300 Al capacity (Beckman, San Ramon, CA, USA).
Supelcosil LC-18 columns (3 Am particle size, 75 4.6
mm) or Beckman ODS Ultrasphere columns (3 Am particle
size, 70 4.6 mm) or Phenomenex Luna C18 (3 Am
particle size, 75 4.6 mm) equipped with guard columns
(Supelguard, 5 Am, 2 cm, or Phenomenex Security guard 4
mm L 3 mm ID) were used.
The RP-HPLC elution procedures for assays conducted
on erythrocytes and plasma have been described [27]. A
gradient of 0.01 M potassium phosphate buffer pH 5.5
(eluant A) and methanol (eluant B), as described for plasma
analysis, was used for the analysis of urine samples. Peak
identities were confirmed by retention time, coelution with
internal standards and 280/260 nm absorbance ratios; con-
centration/area linear plots were developed for quantifica-
tion. A mixture of all standard solutions was injected daily
to check the reliability of separation and any modification of
RTs due to the chromatographic system. Radioactive com-
pounds were separated by Sys 2; the UV trace at 260 nm
and the radioactivity trace were monitored. Radioactive
peak area was converted to count per minute and then
nanomoles according to the specific activity of the precursor
used.
2.4. DNA analysis
Genomic DNA was purified from peripheral blood lym-
phocytes according to Miller [34]. DNA fragments of each
exon, amplified by symmetric followed by asymmetric PCR
[35], were purified with glasspowder (Geneclean, La Jolla)
and directly sequenced (Sequenase, USB, Amersham).
SSCP analysis was performed as described previously [36].
3. Results
3.1. Purine and pyridine enzymes
The activities of the enzymes of purine (PRPS, HPRT,
APRT) and pyridine (NAPRT, NMN/NAMN-AT, and
NADs) metabolism of the propositus and relatives are
reported in Table 1. HPRT activity in erythrocyte lysate of
L.C. was 17% of the normal value and APRT activity was
increased more than twofold. L.C.’s uncle, G.M., showed an
even lower HPRT activity (10%) with APRT activity in the
normal range. HPRT/APRT activity ratio was very low in
both the propositus and G.M. (0.45 and 0.38, respectively)
compared with controls (5.8F 1.6). PRPS activity was
within the normal range in all subjects except G.M., in
whom it was low. NAPRT and NADs activities were higher
than normal in the propositus, but not in G.M.; NMN/
NAMN-AT activities were within the normal range in all
subject. The activities of the purine enzymes ADA and PNP,
Table 1
Purine and pyridine enzyme activities in crude lysates of patient and relatives
Subjects HPRT APRT PRPS NAPRT NMN-AT NAMN-AT NADs
L.C. 23 51 38.2 2.50 0.37 0.29 0.89
Mother 121 20 38.8 1.49 0.25 0.27 –
Father 143 18 43.1 1.42 0.23 0.24 0.24
Brother 118 19 36.4 1.02 0.38 0.26 0.37
Uncle G.M. 11 29 14.1 1.19 0.20 0.22 0.27
Grandmother 77 22 31.3 1.09 0.20 0.19 0.20
Aunt A. 114 24 44.5 1.01 0.20 0.14 0.59
Aunt C. 121 22 43.2 1.25 0.24 0.13 0.45
Aunt R. 98 23 40.1 0.92 0.17 0.14 0.20
Controls
Adults 113F 11 21F 4 37F 9 1.01F 0.27 0.32F 0.08 0.29F 0.08 0.39F 0.11
Children 127F 30 21F 3 41F10 0.87F 0.37 0.437F 0.122 0.35F 0.12 0.45F 0.2
Activities in nmol/h/mg Hb (meanF standard deviation).
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assayed in the propositus L.C. and brother G.C., were within
the control range (control values for ADA: 78F 18 nmol/h/
mg Hb; L.C.:106, G.C.:138; control values for PNP:
4402F 965 nmol/h/mg Hb; L.C.: 5254, G.C.: 4871). The
activities of the pyrimidine enzymes OPRT and ODC were
also within control range in the propositus (OPRT 0.12,
ODC 0.18; children control range 0.33F 0.18 and 0.31F
0.14 nmol/h/mg Hb, respectively) and uncle G.M. (OPRT:
0.31, ODC 0.28; adult control values 0.19F 0.03 and
0.18F 0.03 nmol/h/mg Hb, respectively).
3.2. Metabolites in erythrocyte and plasma extracts and in
urine
Erythrocyte concentrations of nucleotides are reported in
Table 2. NAD levels were twice the normal and UDPs
concentrations were above normal in the propositus, but not
in G.M.; all the other nucleotides were within the age-
matched control range. The finding of the above alterations
in the propositus’ erythrocytes led us to suspect either HPRT
or PNP deficiency [21], but the latter was ruled out. ADP-
ribose (ADPR), produced by NAD breakdown, was also in
the normal range, though at the upper limit in G.M.
Plasma and urine concentrations of some metabolites are
reported in Table 3. Uric acid (UA) concentrations in plasma
were above the normal range in G.M., while hypoxanthine
(Hyp) concentrations were normal; the reverse situation was
found in the propositus, who showed raised levels of
hypoxanthine and normal levels of uric acid; no alteration
was detected in the propositus’ brother. In the propositus,
urinary hypoxanthine and xanthine (Xan) levels were also
above control values; uric acid was also elevated on the
basis of creatinine (crea) excretion (creatinine was 37 mg/dl
in the propositus and 32 mg/dl in the brother; control values
were 81F 45 mg/dl). Plasma concentrations of tryptophan
and Nam, possible NAD precursors, were in the control
range.
3.3. Intact cell studies
The rate of incorporation of radiolabeled hypoxanthine,
adenine, NA and NAm into nucleotides by intact erythro-
cytes is reported in Table 4. The uptake of hypoxanthine
was less than half the control in the propositus, and that of
adenine was double. The ratio of hypoxanthine uptake
versus adenine uptake was lower than controls in the
propositus (0.3, adult controls ranging 1.5F 0.5; and age-
matched controls 0.99F 0.28). Incubation with NA and
NAm yielded mono- and di-nucleotides. NAD was obtained
from both precursors; NAMN and NA adenine dinucleotide
(NAAD) from NA; NMN from NAm. The uptake of NA
and NAm was slightly above that of age-matched controls
Table 2
Nucleotide concentration in erythrocytes of patients and relatives
Subjects AMP ADP ATP GDP GTP UDPs ADPR NAD NADP
L.C. 8 111 1530 14 68 132 4.6 125 39
Uncle (G.M.) 11 120 995 7.5 68 55 12.5 66 41
Mother 11 135 1067 5 64 79 3.6 55 36
Father 24 111 1300 10 80 99 2.3 60 41
Brother 6 126 1526 10 78 82 5.4 72 46
Controls
Adults 16F 14 147F 57 1099F 264 12F 7 71F 29 67F 24 7.2F 3.9 42F 12 36F 9
Children 10F 4 151F 20 1270F 98 13F 9 85F 23 69F 4 9F 6.1 56F 22 41F16
Concentrations in nmol/ml packed cells (meanF standard deviation).
Table 3
Metabolites in plasma and urine of patients and relatives
Subjects Plasma Urine
UA Hyp Xan Trp NAm UA UA/crea Hyp Xan
L.C. 212 54 1.7 51 3.4 61.1 1.66 4.7 22.2
Uncle (G.M.) 356 5.3 3.3 36.8 1.5
Mother 181 2.3 – 35.9 1.0
Father 245 2.5 1.3 34.8 1.0
Brother 143 9.3 6.1 50.1 1.0 24.2 0.75 0.2 1.5
Controls
Adults 263F 57 3.8F 2.9 1.7F 0.8 40.7F 7 3.2F 2.1 48F 24 0.41F 0.2 1.12F 0.4 2.8F 1.7
Children 209F 50 4.2F 2.5 1.9F 0.9 39.5F 11 2.0F 1.8 69F 32 0.98F 0.39 1.13F 0.7 3.7F 2
Concentrations in plasma in nmol/ml; in urine mg/dl (meanF standard deviation).
Trp: tryptophan; Nam: nicotinamide.
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in the propositus (NAMN and NAD productions were
elevated).
3.4. HPRT studies
3.4.1. Apparent kinetic characteristics
The apparent Vmax and Km for both substrates of HPRT
(hypoxanthine and PPRibP) were determined in crude
hemolysates of the propositus and his uncle, parents and
brother. Markedly decreased apparent Vmax (14 and 11
nmol/h/mg Hb in L.C. and G.M., respectively, compared
to 76.3F 3.2 nmol/h/mg Hb in controls) and slightly
decreased apparent Km for hypoxanthine (0.5 and 1.8
Amol/l in L.C. and G.M., respectively, compared to
5.2F 0.2 Amol/l in controls) were found. To our knowledge,
this type of kinetic alteration had not been reported pre-
viously. The Km for PPRibP was within the control range
(43.9 and 37.9 Amol/l in L.C. and G.M., respectively,
compared to 37.5F 8.5 Amol/l in controls).
3.5. Enzyme stability
Recovery of HPRT activity after storage of erythrocytes
at  80j and after heating lysates to 60 jC was measured in
order to check enzyme stability. No difference was found
among patients L.C. and G.M. and controls in either case
(no decay of enzyme activity after storage for up to 3 years
nor after heating for up to 8 min; data not shown).
3.6. Molecular studies
The complete nucleotide sequence of the coding region
of the HPRT gene of patient L.C. showed substitution of
C538 to T in exon 6. This mutation, confirmed by sequenc-
ing of the complementary strand and SSCP, changes leu-
cine-147 into phenylalanine. This is a new variant, not
reported previously, and has been termed HPRTPotenza.
The same mutation was confirmed in uncle G.M. No
alterations were found in any other exon. The mother and
grandmother were heterozygous for the mutation, whereas
the father, brother and mother’s sisters were homozygous
for the normal sequence. Fig. 2 shows sequence analysis of
PCR-amplified DNA of exon 6 of the HPRT gene in closest
relatives. To our knowledge this is the first Italian patient
with partial deficiency in whom mutation of the HPRT gene
has been investigated.
3.7. NAPRT and NADS studies
The increased activity of NAPRT and NADs in crude
lysate of the propositus may be due to an increased number
of active molecules, or the presence of altered molecules, or
Table 4
Production of purine nucleotides from radiolabeled Hyp and Ade (1 h incubation), and of pyridine nucleotides from NA and NAm (6-h incubation) in intact
erythrocytes
Precursor Hyp Ade NA NAm
Products IMP AMP+ADP+ATP NAMN NAAD NAD NMN NAD
Subjects
L.C. 76 235 410 11 105 8.9 11.2
Brother 215 169 370 14 98 11.0 5.1
Controls
Adults 173F 56 106F 27 346F 37 15.1F 8.4 55.9F 27.0 6.1F 2.3 7.2F 2.3
Children 160F 39 169F 37 296F 53 16.3F 8.6 56.7F 17.8 6.5F 4.4 5.04F 3.3
Production rates in nmol/ml erythrocytes (meanF standard deviation).
Fig. 2. SSCP analysis of PCR-amplified DNA of exon 6 of the HPRT gene in closest relatives.
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even the presence of endogenous metabolites activating
both enzymes. The latter hypothesis was ruled out by
comparing the activity measured in lysates from L.C. with
that measured in mixtures of equal volumes of lysate from
the patient and control lysate. No significant increase in
activity with respect to the expected mean value was found
for either enzyme (NAPRT—expected mean for L.C. plus
control 1.28 nmol/h/mg Hb, measured activity 1.37 nmol/h/
mg Hb; NADs—expected mean for L.C. plus control 0.62
nmol/h/mg Hb, measured activity 0.67 nmol/h/mg Hb).
Storage of washed erythrocytes for up to 1 year at
 80jC did not show any difference in enzyme stability
(no significant decay in patients or controls; data not
shown).
4. Discussion
Metabolic and molecular studies were conducted in a
child (L.C.) with severe neurodevelopmental retardation and
his relatives. The child was found to have partial HPRT
deficiency without hyperuricemia, possibly due to the early
age of the child [1], and with mild hyperuricuria. His elder
brother, also mentally retarded with different features
including autistic behavior, had no deficiency in HPRT
activity. Partial deficiency was found in the propositus’
maternal uncle (G.M.) who showed no neurological or gout
symptoms. Metabolic studies involving purine, pyrimidine
and pyridine metabolism, devised to compare results with
findings in complete HPRT deficiency [21,27], were per-
formed in the erythrocytes. Molecular studies aimed at
understanding the predictable consequences of mutation
on HPRT activity were performed on genomic DNA. SSCP
analysis of PCR-amplified DNA of the two partially HPRT-
deficient subjects (L.C., G.M.) confirmed a point mutation
C538T in both and the full nucleotide sequence of genomic
DNA was determined [37]. This mutation has not been
reported previously and the new mutant form of human
HPRT was named HPRTPOTENZA. The propositus’ mother
and grandmother were found to be heterozygous carriers. To
our knowledge, L.C. is the first Italian patient in whom a
mutation of the HPRT gene causing partial deficiency has
been investigated. Moreover, the propositus’ uncle G.M. is
probably the second case of completely asymptomatic
partial HPRT deficiency [28].
Almost 300 different mutations occurring throughout the
HPRT gene have been identified so far and correlation
between mutations and phenotype investigated [5,6]. Stud-
ies lead to the conclusion that identification of mutations
provides a poor tool to predict the phenotypic manifestation.
Mutations leaving some residual enzyme activity are typi-
cally associated with less severe clinical manifestations.
Deletions and duplications within the gene have mostly
been demonstrated to cause complete enzyme deficiency
and LNS; point mutations have been identified in most
patients with either partial or complete deficiency. Con-
served amino acid substitutions are likely to alter HPRT
protein conformation less severely than nonconserved sub-
stitutions. In the mutation described here, the resulting
protein differs from normal HPRT by a single amino acid
(nonpolar leucine vs. nonpolar phenylalanine), yet the
enzyme activity is as little as 17% of normal. The amino
acid substitution found in HPRTPotenza is close to the
hypothesized binding-domain of hypoxanthine, and is
included in a homology area common to other phosphor-
ibosyltransferases [38], which suggests that also Leu147
might be involved in the binding of hypoxanthine. These
data are consistent with the slightly decreased apparent Km
for hypoxanthine found in crude hemolysates of the two
affected subjects also showing decreased Vmax. Different
kinetic alterations have been described in mutant enzymes
such as increased Km for PPRibP [15,39,40] and for
hypoxanthine [41] To our knowledge, the type of kinetic
alteration found in HPRTPotenza had not been reported
previously.
The appreciable conversion of hypoxanthine to IMP in
L.C.’s intact erythrocytes suggests that the deficiency in the
activity of crude lysates may be related to molecular
instability, though the activity did not show significant
decay either after storage or heating. The patient might
therefore have sufficient activity in his cells, as demonstra-
ted by the ratio of hypoxanthine uptake to adenine uptake,
which was one-third the normal value, whereas the ratio of
HPRT activity to APRT activity in lysates was one-tenth the
normal value.
The erythrocytes of the propositus (but not his uncle) had
the typical biochemical features reported in LNS cells
[21,27]: increased APRT activity, increased NAD concen-
trations and related activities of NAPRT and NADs. We
recently reported increased erythrocyte 5V-nucleotidase
activity in the partially deficient child L.C., as well as in a
group of LNS patients [42]. NAD concentrations in eryth-
rocytes of L.C. were twice the controls, possibly due to
increased synthesis through raised activities of NAPRT and
NADs, as suggested in LNS patients [27]. The alteration did
not seem to be caused by increased stability of the two
enzymes [43] or by the presence of intracellular activators,
and is probably related to molecular modifications or
increased synthesis of the two enzymes. OPRT and ODC
activity, often reported to be dramatically elevated in LNS
patients and possibly related to allopurinol treatment [44],
were within the normal range in L.C. and G.M., neither of
whom was on allopurinol therapy. The lack of any bio-
chemical alteration, except for low HPRT activity in G.M.’s
erythrocytes, is puzzling and suggests that partial deficiency
may have different features and vary from one patient to
another. The neurological manifestations in the child were
likely not related to partial HPRT deficiency. In fact they
were absent in the partially HPRT-deficient uncle. More-
over, a severe neurological impairment, though with differ-
ent clinical features, was also present in the elder brother
who had normal HPRT activity. The role of the biochemical
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alterations identified in patient L.C. on the neurological
manifestations is thus unknown.
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